Interview with Chor Eng Cheah, Head of Invidia Malaysia and Singapore, Invida…
When we spoke to Herbert Dittmar of Bayer, he said that there were no specific challenges in Malaysia that could not be found elsewhere. How do you convince companies of…
Address: Level 2, No 10 Jalan Bersatu 13/4, 46200 Petaling Jaya, Selangor, Malaysia
Tel: -15028
Invida improves the lives of patients in Asia by commercializing differentiated pharmaceutical products of superior quality. We do this through our proven brand and sales know-how, strong expertise across a number of key therapeutic categories, and deep experience in all critical Asia Pacific countries. Comprehensive functional capabilities provide rapid market access delivered by our passionate team of professionals.
Invida operates in the fastest growing healthcare markets worldwide, increasing at an annual compounded growth rate of 12 percent, more than double the global growth rate for the sector. Today, the Asia Pacific markets represent approximately US$50 billion and 10 percent of worldwide pharmaceutical sales.* With China and India among top growth contributors globally, Invida is currently implementing a long-term strategy to establish itself as a leader in these rapidly expanding markets through targeted investments.
With more than 4,000 employees throughout Asia Pacific, Invida operates throughout the commercial value chain from regulatory approval and product launch to lifecycle management. We manage a portfolio of proprietary healthcare brands as well as licensed products from biotech and multinational companies. Partnering is a critical component of Invida’s business model.
When we spoke to Herbert Dittmar of Bayer, he said that there were no specific challenges in Malaysia that could not be found elsewhere. How do you convince companies of…
The Pharmaceutical Services Division has been around since 1951, what have been the major shifts in its objectives since then? When the pharmacy service came into existence in this country…
One of the key factors for the growth in the pharmaceutical market has been the increasing professionalism of healthcare in Malaysia. How does the MMA contribute to the professionalism of…
When we spoke to Herbert Dittmar of Bayer, he said that there were no specific challenges in Malaysia that could not be found elsewhere. How do you convince companies of…
Would you give our readers an insight into the government’s attempts to foster a better environment for FDI in Malaysia? Over the last year, the significant development has been the…
Before joining Nycomed you spent a year working at the Drug Control Authority (DCA). What did your regulatory friends say when you told them you were off to join the…
Can you give our readers an outline of Bayer’s background in Malaysia and its current organisational division? Herbert Dittmar (HD): Bayer has been in Malaysia for around fifty years. It…
Kebangsaan Malaysia (UKM). Singapore and Taiwan are known for their high level of basic research and their focus on Biotechnology. Philip Yeo, Chairman of Spring Singapore told us that Biomedical…
Nowadays we can talk of an abundance of information coming from companies like Frost& Sullivan, IMS and even consultancies who are producing their own data. As a leader in market…
You have worked in the pharmaceutical industry for many years starting with Novartis and you have spent the last eight years working for Lundbeck. What are the major changes that…
Pharmaceutical Executive is a magazine about executives, their experience and their perspectives on the pharmaceutical industry. You have worked in Australia, Hong Kong and now you are the general manager…
You spent most of your career in the pharmaceutical industry with Bristol Meyers Squibb and earlier on for NV Organon which you joined in 1998. In 2007 you left to…
You have spent much of your time working in the USA and came to Malaysia in 2008 as Country Manager. What were your expectations of Malaysia before you arrived and…
See our Cookie Privacy Policy Here
